gehrig s disease

Preliminary but encouraging findings from a Phase 0 human clinical trial of a melanoma drug have been reported. Scientists found an approved drug used to treat Lou Gehrig's disease (ALS), slows the growth of melanoma, the most aggressive form of malignant skin cancer.

In recent months a spate of mutations have been found in a disease protein called TDP-43 that is implicated in two neurodegenerative disorders: amyotrophic lateral sclerosis, also called Lou Gehrig's disease, and certain types of frontotemporal dementia.

These mutations could potentially become candidates for drug targets. Recently, scientists have found two more mutations.